Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure

Objective: to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.

Materials and methods: 111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consisted of 25 patients with CHD, CHF II-III FC and thyrotoxicosis; the 1st group of comparison - 30 patients with CHD and CHF II-III FC, without thyrotoxicosis; the 2nd group — 30 patients with thyrotoxicosis without CHD, the 3rd group - 26 patients with thyrotoxicosis and CHD, with no signs of CHF. Te fnding of thyroid gland, the level of NT-proBNP was estimated at baseline and afer 6 months therapy. A new cut-off NT-proBNP for the diagnosis of CHF in comorbid patients was calculated by using ROC analysis.

Results: the high concentration of NT-proBNP was detected in all patients (more then 125 pg/ml), in the 2nd comparison group — 225.5 (180.1, 376.1) pg/ml. Te NT-proBNP values in the patients of the 1st and 3rd comparison groups did not differ signifcantly. Te highest level of NT-proBNP was detected in the main group — 712.1 (434.3, 893.9) pg/ml. A cut-off of this marker for screening CHF in comorbid patients with CHD and thyrotoxicosis was calculated - 556.4 pg/ml (a sensitivity of 72 %, a specifcity of 100 %, an accuracy of 87.2 % (p <0.001)). Afer 6 months therapy in the 2nd comparison group the level of NT-proBNP decreased by 74 % (р<0,0001) and has reached the normal value (64,6 (42,2;76,3)); in the main group the level decreased by 43% and was 406,7 (309,1; 498,6) pg/ml.

Conclusions: the patients of all groups showed an increased concentration of NT-proBNP. Te highest level of NT-proBNP was observed in the group of patients with CHF by CHD and thyrotoxicosis. Te level of NT-proBNP was determined - 556.4 pg/ml, which allows us to diagnose CHF in patients with a combination of CHD and thyrotoxicosis.

1. Larina VN, Chukaeva II. Diagnosis and Treatment of Chronic Heart Failure (based on 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure). Lechebnoe delo (Medical Care, Russian journal). 2016;6:37-48. (in Russ).

2. Mareyev VYU., Fomin IV., Ageyev FT., Arutyunov GP., Begrambekova YUL., Belenkov YUN. at al. Clinical recommendations. Chronic heart failure (CHF). Journal Serdechnaya Nedostatochnost’. 2017;18(1):3–40. (in Russ). doi: 10.18087/rhf.2017.1.2346

3. Fomin IV. Chronic heart failure in the Russian Federation: what we know today and what should be done. Rossiyskiy kardiologicheskiy zhurnal (Russian Cardiology Journal). 2016;(8):7–13. (in Russ). doi:10.15829/1560-4071-2016-8-7-13

4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur Heart J. – 2016. - №37. – С. 2129-2200. DOI:10.1093/eurheartj/ehw128

5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;(1):7-81. (In Russ.) doi: 10.15829/1560-4071-2017-1-7-81

6. Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol. 2012;167(5):609-18. doi: 10.1530/EJE-12-0627167609-618

7. Biondi B., Kahaly G.J. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nature Reviews. Endocrinology. 2010;6:431–443. doi:10.1038/nrendo.2010.105

8. Aliyeva AM, Nikitin IG, Starodubova AV, Gogova LM, Gromova OI, Baykova IE at al., Diagnostic and prognostic signifcance of natriuretic peptides in cardiac patients. Lechebnoe delo (Medical Care, Russian journal). 2016;3:78-84 (in Russ).

9. Israilova VK, Dzholdybekov TS, Batyrbayeva DZH, Utegenova ZHA, Muratova AM, Serekov AG. Te value of tests for the determination of natriuretic hormone (B-type) in cardiac practice (Literature review). Vestnik KazNMU. 2016;4:314-316 (in Russ).

10. Fedotova IN, Belopol’skiy AA, Sturov NV. Te diagnostic signifcance of NT-proBNP in cardiac patients. Trudnyy patsiyent (Difcult patient). 2013;11(7):22-32 (in Russ).

11. Burnasheva GA, Napalkov DA. Natriuretic peptides: use in modern cardiology Vestnik RAMN. 2015;70(5):568–572. (in Russ). doi: 10.15690/vramn.v70.i5.1443

12. Andryukov BG, Akimenko VB, Demyanenko NB, Matveyev ON, Polovov SF, SHendrikova EV. An increase in the blood content of the atrial natriuretic peptide in patients with thyrotoxic syndrome is a predictor of the formation of heart failure. Fundamental’nyye issledovaniya. 2008;2:27-28 (in Russ).

13. DeFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger S.L. Dynamic cardiovascular risk assessment in the elderly: Te role of repeated amino terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55(5):441–450. doi: 10.1016/j.jacc.2009.07.069

14. Ozmen B, Ozmen D, Parildar Z, Mutaf I, Bayindir O. Serum N-terminal-pro-B-type Natriuretic Peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Journal Endocr. Res. 2007;32(1-2):1-8.

15. Ertugrul DT, Gursoy A, Sahin M, Unal AD, Pamuk B, et al. Evaluation of Brain Natriuretic Peptide Levels in Hyperthyroidism and Hypothyroidism. Journal of the National Medical Association. 2008;100(4):401-405. doi: 10.1016/S0027-9684(15)31272-4

16. Kato K, Murakami H, Isozaki O, Tsushima T, Takano K. Serum concentrations of BNP and ANP in patients with thyrotoxicosis. Endocrine Journal. 2009;56(1):17-27. doi: 10.1507/endocrj.k08e-145

17. Pakuła D., Marek B., Kajdaniuk D. Plasma levels of NT-probrain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol. 2011; 62(6):523-8.

18. Schultz M, Faber J, Kistorp C, Jarløv A, Pedersen F, еt al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004;60(1):54-9. doi: 10.1111/j.1365-2265.2004.01941.x

19. Li X, Yang X, Wang Y, Ding L, Wang J, Hua W. Te Prevalence and Prognostic Effects of Subclinical Tyroid Dysfunction in Dilated Cardiomyopathy Patients: A Single-Center Cohort Study. Journal of Cardiac Failure. 2014;20(7):506-512. doi:10.1016/j.cardfail.2014.05.002

20. Tarbeyeva NS, Smirnova EN An integrated approach in detecting cardiovascular dysfunction in patients with thyrotoxicosis. Sovremennyye problemy nauki i obrazovaniya. 2015; 3. Available from: http://www.science-education.ru/ru/article/view?id=19851 (Accessed on January 30, 2018) (in Russ).

21. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007 Apr; 93(4):483–487. doi: 10.1136 /hrt.2006.100628.